Evgen's SFX-01 selected for COVID-19 trial
admin 17th June 2020 Uncategorised 0The company is participating in LifeArc’s funding initiative for COVID-19 clinical trials More: Evgen's SFX-01 selected for COVID-19 trial Source: News
read moreThe company is participating in LifeArc’s funding initiative for COVID-19 clinical trials More: Evgen's SFX-01 selected for COVID-19 trial Source: News
read moreThe drug will be funded on the NHS to treat ulcerative colitis under certain conditions More: Final NICE green light for Janssen's Stelara in UC Source: News
read moreThe deal gives GSK access to IDEAYA’s MAT2A, Pol Theta, and Werner Helicase programmes More: GSK and IDEAYA partner in synthetic lethality Source: News
read moreThe move follows data from the RECOVERY trial showing no beneficial effect of the drug in patients hospitalised with COVID-19 More: MHRA suspends COVID-19 hydroxychloroquine trials Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals